Q-omics provides the consensus-scored MFSD14A profile across patient tissues and cancer cell-line models. MFSD14A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MFSD14A is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MFSD14A RNA expression shows 20,190 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where MFSD14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD14A survival associations across molecular data types. MFSD14A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD14A RNA expression–survival associations across cancer types. High MFSD14A expression shows unfavorable associations in SCLC, LIHC, LGG, ACC and HNSC, but favorable associations in KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MFSD14A RNA expression.
This table summarizes MFSD14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD14A shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher MFSD14A RNA expression in tumor versus normal tissue (log2 FC = +0.782, t-test p < 0.001).
This table shows molecular features associated with MFSD14A in patient tissues and cancer cell lines. In patient samples, MFSD14A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
